Pangea Biomed, the company behind the world’s most advanced cancer response predictor, ENLIGHT, today announced that new findings establishing the efficacy of its novel ENLIGHT-DP platform have been published in Nature Cancer. The study, conducted in collaboration with researchers from the Australian National University and from the US National Cancer Institute, reveals that combining ENLIGHT with the DeepPT approach for inferring gene expression from H&E slide scans significantly advanced the ability to predict therapeutic responses across multiple cancer types and drugs from histopathology images.